key: cord-0837943-gwkiuats authors: Schauer, Jenna; Buddhe, Sujatha; Colyer, Jessica; Sagiv, Eyal; Law, Yuk; Chikkabyrappa, Sathish Mallenahalli; Portman, Michael A. title: Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents date: 2021-07-03 journal: J Pediatr DOI: 10.1016/j.jpeds.2021.06.083 sha: a986e8b76cf48d3d8c9ec17edbe684862ada1d41 doc_id: 837943 cord_uid: gwkiuats Reports have emerged of myocarditis and pericarditis predominantly after the second dose of the coronavirus disease messenger ribonucleic acid vaccine. We describe 13 patients aged 12-17 years who presented with chest pain within 1 week after their second dose of the Pfizer vaccine and were found to have elevated serum troponin levels and evidence of myopericarditis. dose of the COVID-19 mRNA vaccine. We describe 13 patients 12-17 years of age who presented with chest pain within 1 week after the second dose of the Pfizer vaccine and were found to have elevated serum troponin levels and evidence of myopericarditis. The FDA extended the emergency use authorization of the Pfizer-BioNTech mRNA COVID-19 vaccine for adolescents 12 through 15 years of age on May 10, 2021 [1] . Following authorization large numbers of adolescents across the country began to receive immunization. As of June 21, 2021, 98,008 adolescents 12 through 15 years of age and 69,489 adolescents 16 and 17 years of age in Washington state completed the 2-dose schedule of mRNA COVID-19 vaccine [2] . Reports of post-COVID-19 vaccine myocarditis and pericarditis have emerged , particularly after the second dose of the mRNA vaccines. Initial cases were noted predominantly in male adolescents and young adults in the Israeli military [3] . Subsequently, U.S. institutions have reported 7 cases in adolescents over 16 years old [4] and 7 cases in young adults [5] . As the age range of eligibility for the COVID-19 vaccine broadened in Washington state we have cared for a cohort of younger patients with post-vaccine myopericarditis. We describe clinical and cardiac MRI (CMR) findings for 13 patients 12 through 17 years of age cared for in our center. We performed a retrospective electronic medical record review. Institutional Review Board approval was obtained. Inclusion criteria were patients younger than 18 years of age All patients had elevated serum troponin levels (median 9.18 ng/mL, range 0.65-18.5). Median serum B-natriuretic peptide level was 37.5 pg/mL (range 7-87pg/mL). CRP was elevated in patients in whom CRP was measured (N=10, median 3.7 mg/dL, range 1.4-6.5 mg/dL) COVID-19 nucleocapsid IgG antibody was measured in 9 patients and was negative in all. Cardiac testing and results are shown in Table II imaging and fulfilled the Lake Louise Criteria [6] for myocarditis. Left ventricular regional wall motion abnormalities were noted in 2 patients; CMR based LV systolic function was mildly decreased in 8 patients. The CMR LVEF ranged from 46-61%, median 53%. No significant pericardial effusions were seen on CMR. All patients received scheduled doses of nonsteroidal anti-inflammatory agents (ie, ibuprofen every 8 hours with dose dependent on patient weight). Three patients received intravenous immunoglobulin (IVIG), 2 of whom were the patients with decreased left ventricular function by echocardiography. These 2 patients also received corticosteroids per our institutional pathway for treatment of myocarditis. One patient had isolated premature ventricular contractions on telemetry; no other patient had evidence of arrhythmia. Median hospital length of stay was 2 days (range 1-4 days) with no ICU admission, significant morbidity, or mortality. All patients had resolution of chest pain and falling serum troponin level prior to discharge. We report 13 adolescents with myopericarditis after the second dose of the Pfizer mRNA COVID vaccine. This cluster of cases was identifiable as age of vaccination for eligibility broadened with emergency use authorization by the FDA. We are the only free-standing children's hospital in Washington state and serve as a tertiary referral institution. To our knowledge, at least 3 other cases in this age group have been cared for at other hospitals in the state. Using these numbers and Washington state Department of Health data on immunization [2] we estimate a possible incidence of 0.008% in adolescents 16-17 years of age and 0.01% in those 12 through 15 years of age following the second dose. All patients had evidence of myocardial inflammation and edema on CMR, similar to findings in limited case series of adults with post-COVID-19 vaccine myocarditis [7] . Although all patients' symptoms resolved rapidly, the CMR findings indicate the potential for myocardial fibrosis and unknown long-term impact. Accordingly, we are following the AHA/ACC acute myocarditis recommendations for exercise restrictions of up to 6 months and long-term cardiac surveillance [8] . Additionally, follow up CMR is planned for all patients at 3 months, which may allow us to shorten the period of exercise restriction. We speculate that a hyperimmune response to the second dose of the vaccine is plausible. Children have demonstrated a more robust immune response to SARS-CoV-2 infection than adults as observed with multisystem inflammatory syndrome in children (MIS-C) [9] . For noninferior immunogenicity it is possible the interval between doses 1 and 2 should be longer in children than in adults or that a reduction in content of dose 2 would be appropriate in people less than 18 years of age. It is noteworthy that 2 of our cases had a family history of myocarditis in first degree relatives. There is evidence that genetics may play a role in the susceptibility of patients to myopericarditis [10] . This predisposition may increase the likelihood of inflammation and cardiac effects after the vaccine. The Pfizer Phase 2/3 clinical trial included only 754 participants in the 16 and 17 year old age group and 2,260 in the 12 to 15 year old age group. Approximately 50% were male [11] . As noted, we have estimated the incidence of myopericarditis in the younger group near 0.01% of those receiving second dose vaccines. Due to reporting issues, delays, and early inability of practitioners to associate myopericarditis with vaccine this value is likely an underestimate. Additionally, our Washington state Department of Health vaccine data for these age groups are FDA Emergency Use Authorization for Pfizer-BioNTech COVID-19 Vaccine Washington State Department of Health. COVID-19 Data Dashboard Myocarditis following COVID-19 mRNA vaccination Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech Vaccination Myocarditis Temporally Associated with COVID-19 Vaccination Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings Diagnosis and treatment of myocarditis in children in the current era Characteristics and Outcomes of US Children and Adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19 Myocarditis: Which Role for Genetics? Pfizer-Biontech announce positive toppling results of pivotal COVID-19 vaccine study in adolescents 2021